Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
· seekingalpha.com
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis after the FDA’s feedback for a clearer path. Learn why CGTX stock is a buy.
My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, ...